To assess whether chemotherapeutic agents could trigger senescence in CRC cells in vitro, CPT-11, an inhibitor of DNA topoisomerase I that has been commonly applied in CRC patients, was utilized to treat p53-wild type CRC cell lines HCT116 and RKO. The gene discussed is TP53; the disease is colorectal carcinoma.